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Abstract
Aims Little is known regarding initiation of insulin therapy in type 2 diabetes (T2D) in Central and South-Eastern Euro-
pean countries. Therefore, we conducted a survey to characterise the prescribing practices of specialist diabetes healthcare 
professionals in this region and assessed factors that influence clinical decision-making regarding insulin initiation in T2D.
Methods A cross-sectional survey sampled 211 specialist diabetes healthcare prescribers from five Central and South-
Eastern European countries (Bulgaria, Croatia, Greece, Hungary, and Slovenia). A structured questionnaire was developed 
which surveyed current clinical practices and influencing factors, barriers to insulin initiation, and combination therapy 
prescribing preferences.
Result Only 9.4% (20 of out of 211 respondents) of healthcare professionals would initiate insulin therapy in T2D patients at 
the recommended HbA1c threshold of 7–7.9% [53–63 mmol/mol]. Large regional differences were evident in insulin initiation 
thresholds (≥ 9.0% [≥ 75 mmol/mol]: Bulgaria 80.8% vs. Slovenia 13.3%). Psychological distress was recorded as the major 
barrier to insulin initiation. Health insurance regulations were ranked more important than personal clinical experience and 
clinical guidelines in clinical decision-making. Information from peers was more influential than manufacturer information, 
clinical experience, and continuous medical education, respectively, for insulin initiation.
Conclusions Despite large regional variation, there is widespread delay of insulin initiation from specialist diabetes healthcare 
professionals in Central and South-Eastern Europe.
Keywords Insulin therapy initiation · Type 2 diabetes mellitus · Clinical inertia
Introduction
Type 2 diabetes (T2D) is one of the greatest global health 
emergencies of today with almost a half a billion people liv-
ing with the disease [1]. To lessen the burden of T2D, there 
is an urgent need for responsive, responsible, and effective 
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clinical care. Through large clinical trials, it is understood 
that intensive glucose control prevents microvascular com-
plications [2] and improves cardiovascular outcomes [3] in 
adults with T2D. In Europe, as well as the USA [4], clini-
cal care guidelines stipulate early adoption of insulin and 
escalation as part of intensifying T2D treatment to aggres-
sively lower glycated haemoglobin (HbA1c) below a general 
target of 7% (53 mmol/mol). However, it is also understood 
that insulin initiation is often inappropriately delayed [5], 
resulting in an unnecessary increased risk of complications 
and needlessly reduced life expectancy and quality of life 
[6]. This has been termed ‘clinical inertia,’ and can be due 
to a number of factors including clinical concerns (i.e. risk 
of weight gain, hypoglycaemia, or patient distress), profes-
sional concerns (e.g. lack of clinical experience, skills, or 
confidence in insulin titration), or health system concerns 
(competing priorities, regulatory or financial constraints, 
or a lack of impartial continued medical education [CME]) 
[7–13]. Recently, a systematic review highlighted the global 
widespread extent of clinical inertia in the management of 
hyperglycaemia in T2D including studies from the USA 
(29 studies), Europe (20 studies), and Asia (3 studies) [5]. 
However, available European studies typical sample from 
northern European countries including the UK, France, 
Spain, and the Netherlands [5], with only one study assess-
ing clinical inertia from Central and South-Eastern European 
regions (one study in Croatia) [14]. Countries in Central 
and South-Eastern Europe compare poorly to countries in 
northern Europe due to a number of factors including dif-
ferent healthcare systems, treatment availability, and clinical 
training. As such, we aimed to comprehensively characterise 
the prescribing practices of specialist diabetes healthcare 
professionals across Central and South-Eastern European 
countries and assess the factors that influence their clinical 
decision-making regarding insulin initiation in T2D.
Methods
The Study of Insulin Therapy Initiation in type 2 diabetes 
in routine clinical Practice (SITIP) is an ongoing multicen-
tre international cross-sectional observational epidemio-
logical study of factors which influence insulin initiation 
in type 2 diabetes. A cross-sectional survey was performed 
between September 2017 to January 2018, on 233 actively 
prescribing specialist diabetes healthcare professionals 
residing across five Central and South-Eastern European 
countries (Bulgaria, Croatia, Greece, Hungary, and Slove-
nia). Study participants were recruited through invitation 
from participating National Diabetes Associations as well 
as through the Advances in Diabetes and Insulin Therapy 
(ADIT) conference database. Following appropriate institu-
tional ethical review, Informed consent was obtained from 
all individual participants included in the study. The sample 
(n = 211) represents 21.4% of all 987 prescribing specialist 
diabetes healthcare professionals within the region (Bul-
garia n = 52 [24.9%]; Croatia n = 19 [9.0%]; Greece n = 51 
[24.3%]; Hungary n = 73 [34.9%]; Slovenia n = 15 [6.9%]). 
Sample size was calculated with regard to confidence inter-
vals (CI) for frequencies: a 95% CI of 10–15% for questions 
answerable was considered narrow enough. This required a 
sample size of ~ 200 persons. A structured 17-item closed 
multiple choice questionnaire was designed to collate pop-
ulation demographic information alongside prescription 
preferences, as well as habits and attitudes towards insulin 
initiation in T2D using Likert items; the questionnaire was 
devised by the research team and is shown in supplement 1.
Statistical analysis
All analyses were performed with SPSS statistical software, 
version 23 (IBM SPSS Software, IBM Analytics), with sig-
nificance set at p < 0.05. Descriptive statistics were mainly 
used with continuous variables (i.e. data collected using 
scaled parameters) and presented as mean ± standard devia-
tion (SD), unless otherwise specified, and categorical data 
(i.e. prevalence) presented as absolute number and percent-
age. The Chi square test was used for comparisons of cat-
egorical data (Yates continuity corrected for comparisons 
with one degree of freedom). Two-sided p values of less 
than 0.05 were considered significant. With regards to con-
tinuous data, regional response rates were weighted to an 
appropriate share.
Results
Remarkably, only 9.4% of healthcare professionals would 
initiate insulin therapy at the recommended HbA1c thresh-
old of 7–7.9% ([53–63 mmol/mol]; Table 1). Almost half 
of the healthcare professionals (47.4%) would initiate insu-
lin therapy at an HbA1c threshold of ≥ 9.0% (≥ 75 mmol/
mol), and 8.0% would not initiate insulin until a threshold of 
≥ 10.0% (≥ 86 mmol/mol) was reached (Table 1). 
As shown in Table 1, when assessing data by region, 77.0% 
of respondents from Bulgaria would only initiate insulin ther-
apy when an HbA1c threshold of ≥ 9.0% (≥ 75 mmol/mol) 
was reached, of which 96.2% would not initiate insulin until 
≥ 10.0% (≥ 86 mmol/mol). In Hungary, 26.6% of respondents 
would only initiate insulin therapy at an HbA1c a threshold 
of ≥ 9.0% (≥ 75 mmol/mol), of which 85.3% would not ini-
tiate insulin until a threshold of ≥ 10.0% (≥ 86 mmol/mol) 
was reached. Conversely, in Slovenia, 13.3% of respond-
ents would initiate insulin therapy at an HbA1c threshold 
of ≤ 9.0 (≤ 75 mmol/mol) and 13.3% would initiate insulin 
therapy at an HbA1c threshold of 7–7.9% (53–63 mmol/mol). 
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Predominantly, basal insulin was primarily selected when ini-
tiating insulin therapy (78.6% of respondents), followed by 
basal-bolus (11.9%), biphasic (9.0%), and prandial (0.5%) 
insulin.
Psychological distress was recorded as the most preva-
lent barrier to insulin initiation across the region and risk of 
hypoglycaemia the least prevalent (Table 1); weight gain was 
considered secondary to quality of life as a barrier to insulin 
initiation. Factors influencing clinical decision-making were 
consistent across the region; health insurance regulations 
and constraints were listed as the most important determin-
ing factor. Conversely, clinical guidelines were the consid-
ered the least important factor influencing clinical decision-
making (Table 1). The most important factor specifically 
influencing insulin initiation was information from peers, 
followed by manufacturer information, with CME ranked 
lowest.
Discussion
This is the first study to comprehensively examine the pre-
scribing practices and factors of influence of specialist dia-
betes healthcare professionals regarding insulin initiation in 
T2D across Central and South-Eastern European countries. 
In this large (n = 211) cohort, we show a high prevalence 
of clinical inertia, with only ~ 10% of prescribers initiat-
ing insulin therapy at the recommended HbA1c threshold 
of 7–7.9% (53–63 mmol/mol). Moreover, almost half the 
healthcare professionals sampled were orientated towards 
initiating insulin therapy in patients if an HbA1c thresh-
old of ≥ 9.0% (≥ 75 mmol/mol) was met, with a further 
~ 10% only initiating insulin when a threshold of ≥ 10.0% 
(≥ 86 mmol/mol) was reached. Further, we highlight sub-
stantial regional differences in the clinical approach to insu-
lin initiation in T2D. For example, almost 80% of respond-
ents from Bulgaria would only initiate insulin therapy in 
T2D at an HbA1c a threshold of ≥ 9.0% (≥ 75 mmol/mol), 
of which ~ 95% would not initiate insulin until a thresh-
old of ≥ 10.0% (≥ 86 mmol/mol) was reached, compared 
to < 15% of prescribers in Slovenia. These results indicate 
Table 1  Composite and regional data regarding clinical practice and influences of clinical practice in insulin initiation and alternative therapies 
in T2D
Note: Continuous data are presented as mean ± SD, and categorical data are presented as %
Composite Bulgaria Croatia Greece Hungary Slovenia Test statistic
HbA1c
 7.0–7.9% [53–63 mmol/mol] 9.4% 1.9% 10.5% 19.2% 6.7% 13.3% –
 8.0–8.9% [64–74 mmol/mol] 43.2% 17.3% 47.4% 46.1% 52.0% 73.3% –
 9.0–9.9% [75–85 mmol/mol] 39.4% 77.0% 36.8% 28.9% 26.6% 13.3% –
 ≥ 10.0% [≥ 86 mmol/mol] 8.0% 3.8% 5.3% 5.8% 14.7% 0.0% –
Clinical barriers to insulin initiation
 Hypoglycaemia 1.84 ± 1.05 2.11 ± 1.21 1.80 ± 1.06 1.56 ± 0.89 1.85 ± 1.06 1.79 ± 0.79 p = 0.148
 Weight gain 2.37 ± 0.94 2.33 ± 1.05 2.13 ± 0.87 2.63 ± 0.91 2.18 ± 0.78 2.83 ± 1.19 p = 0.011
 Psychological distress 3.06 ± 1.04 2.65 ± 1.10 3.26 ± 0.92 2.98 ± 1.13 3.38 ± 0.86 2.86 ± 1.08 p = 0.001
 Quality of life 2.74 ± 1.05 2.91 ± 0.96 2.80 ± 1.08 2.83 ± 0.97 2.58 ± 1.13 2.52 ± 1.17 p = 0.344
Factors influencing clinical decision-making
 Clinical guidelines 1.52 ± 0.71 1.54 ± 0.69 1.70 ± 0.83 1.34 ± 0.65 1.58 ± 0.73 1.62 ± 0.63 p = 0.135
 Health insurance constraints 2.35 ± 0.79 2.28 ± 0.83 2.43 ± 0.79 2.71 ± 0.51 2.16 ± 0.85 2.17 ± 0.82 p = 0.004
 Clinical experience 2.12 ± 0.72 2.17 ± 0.74 1.87 ± 0.70 1.95 ± 0.63 2.26 ± 0.70 2.21 ± 0.92 p = 0.136
Factors influencing insulin initiation practices
 Clinical experience 2.07 ± 0.91 2.22 ± 0.87 2.04 ± 1.05 2.02 ± 0.79 2.08 ± 1.00 1.72 ± 0.86 p = 0.201
 Information from peers 3.14 ± 1.00 3.20 ± 1.09 3.20 ± 0.95 3.12 ± 1.05 3.16 ± 0.92 2.79 ± 1.00 p = 0.000
 Manufacturer information 2.77 ± 1.07 2.57 ± 1.05 3.09 ± 0.88 2.88 ± 1.07 2.66 ± 1.12 3.21 ± 0.96 p = 0.714
 CME education 2.02 ± 1.07 2.02 ± 1.12 1.67 ± 0.83 1.98 ± 1.08 2.09 ± 1.07 2.28 ± 1.18 p = 0.119
Approach to insulin initiation
 Basal insulin 78.6% 67.3% 88.8% 96.0% 73.0% 75.0% –
 Biphasic insulin 9.0% 25.0% 11.2% 2.0% 0% 18.7% –
 Prandial insulin 0.5% 1.9% 0% 0% 0% 0% –
 Basal-bolus 11.9% 5.8% 0% 2.0% 27.0% 6.3% –
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that only the most poorly controlled patients, as opposed to 
all patients with evidence of inadequate glycaemic control, 
are likely to receive timely insulin initiation and that this is 
in part dependent upon country of residence. Our findings 
compliment and extend other large multinational studies 
reporting clinical inertia with regards to insulin initiation in 
T2D in Europe and elsewhere [15, 16].
Preference of basal insulin as the initial choice of insulin 
therapy is supported by the observation that basal insulin 
is often judged easier to use and with less risk of hypo-
glycaemia and weight gain. Further, although a premixed 
and a basal-bolus regimen have been found to yield greater 
reductions in HbA1c, compared to basal-only therapy, both 
are associated with weight gain, increased hypoglycaemia, 
and inconvenience [17, 18].
Previously, physician-, patient-, and healthcare system-
related factors have been identified as contributing factors 
to clinical inertia in insulin initiation [19]. In our study, we 
identified consistent patterns in factors influencing clinical 
decision-making across the region. Our study participants 
ranked health insurance regulations and constraints as the 
most important factor influencing prescription practices, 
with clinical guidelines ranked as the least important fac-
tor. Further, patient distress was highlighted as the most 
important factor influencing clinical decisions, whereas 
risk of hypoglycaemia and potential weight gain as the least 
important factors. In the countries we sampled from, there 
is restricted regional availability of blood glucose self-mon-
itoring (BGSM) reimbursement [20], and increasing BGSM 
increases the patient burden of managing T2D [21].
Our data indicates that healthcare professionals within 
the region turn primarily to peers and manufacturer infor-
mation to guide and inform insulin initiation practices and 
that such practices are informed least from CME. Whereas 
some research has suggested that healthcare professionals 
perceive industry influence to be low [22], the reality is 
that the pharmaceutical industry is often a key source of 
information regarding new products and treatment options 
[23]. Indeed, several studies have shown that physicians are 
susceptible to the pharmaceutical industry and interactions 
with pharmaceutical sale representatives and that this influ-
ences prescribing practices [24–26]. In our study, we cannot 
rule out that the availability of increasing numbers of non-
insulin antidiabetic agents and a lack of accessible independ-
ent CME could foster a reluctance to use insulin among our 
healthcare professionals. The concept of evidence-based 
medicine, defined as the integration of best research evi-
dence with clinical expertise and patient values, is consid-
ered an integral part of medical training and should be effec-
tively integrated into independent, non-industry sponsored 
CME courses [27]. Alarmingly however, our findings sug-
gest that the majority of healthcare professionals within Cen-
tral and South-Eastern European regions may not implement 
clinical guidelines and may not use evidence independent 
of industry to inform T2D treatment. As such, there is an 
urgent need to provide accessible CME courses independ-
ent of industry influence to prescribing specialist diabetes 
healthcare professionals within this region.
In conclusion, we provide new evidence which highlight 
a high level of clinical inertia regarding insulin initiation in 
T2D by prescribing diabetes specialist healthcare profes-
sionals in Central and South-Eastern Europe. We provide 
valuable insight into the factors influencing prescribing 
practices and clinical decision-making which highlight the 
urgent need to provide CME courses independent of industry 
in this region.
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